Addressing highly unmet neurogenerative disorders such as Parkinson's and Alzheimer's diseases with multiple drug candidates through innovative delivery options.

Our Science
- Excellent Animal Proof of Concept
- Multiple mechanism of actions (MOAs)
- Precision Medicine
- Patient-focused Model

Contact Us
Your opinion is important for us to understand and address these challenging neurodegenerative diseases. Please drop us a message if you are interested in learning more of our science and drug development program.
Press Releases
18 Jan 2022
20 Jul 2021
EINPRESSWIRE
FHL Announces Phase 2 Clinical Trial for Parkinson’s Drug, Korean Medical Device Company Acquisition and Saudi JV
09 Apr 2021
09 Apr 2021
26 Mar 2021
Parkinson’s News Today
Forest Hills Lab Asking to Open Phase 2 Trial of FHL-301 in Parkinson’s
24 Mar 2021
Yahoo Finance
Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson’s disease with the US FDA